Interviews

Fátima Rodriguez, MD, explains how the new cardiovascular-kidney-metabolic (CKM) syndrome guideline addresses health equity, risk prediction, and the pharmacist's role in care.

Cheeley takes listeners inside her clinical decision-making process—from statin intolerance to PCSK9 inhibitors to omega-3s—and explains why patient buy-in is as important as the prescription itself.

At ACTHIV 2026, Jaimee Colvin, MSN, APRN, FNP-C, outlined how provider knowledge gaps, entrenched stigma, and a lack of culturally representative outreach continue to drive the PrEP disparity among cisgender Black and Brown women.

Jaimee Colvin, MSN, APRN, FNP-C, outlines the intentional, community-rooted, and representation-driven infrastructure required to scale PrEP access for cisgender women nationally.

Correcting the misinformation around statins and cardiovascular disease, and reframing Lp(a) as a genetic condition, not a personal failure, can be a powerful clinical tool.

Craig Beavers, PharmD, discusses transthyretin amyloidosis cardiomyopathy (ATTR-CM) red flags, treatment evidence, and how pharmacists can drive earlier diagnosis and improve patient outcomes.

Persistent HIV stigma, provider reluctance, and harmful misconceptions about who PrEP is for continue to prevent cisgender Black and Brown women from accessing lifesaving prevention.

New data from the phase 3 DeLLphi-304 trial suggest tarlatamab significantly improves intracranial efficacy outcomes, CNS progression-free survival, and overall survival in patients with relapsed small cell lung cancer (SCLC) and baseline brain metastases.

Jessica Dunne, PhD, discusses why adult type 1 diabetes (T1D) is frequently misdiagnosed as T2D in patients with gestational diabetes mellitus (GDM) and how autoantibody testing could close the diagnostic gap.

Joseph Saseen, PharmD, discusses how pharmacists can overcome therapeutic inertia and sequence nonstatin therapies to help patients reach individualized LDL-C goals.

Advances in Alzheimer disease diagnosis and treatment are reshaping care, highlighting the pharmacist’s role in medication management, patient education, and overcoming barriers to access.

Cisgender Black and Brown women remain significantly underserved by PrEP due to provider knowledge gaps and medical mistrust.

Gonzelez describes advances in Alzheimer disease diagnostics and disease-modifying therapies and highlights the critical role pharmacists play in medication management, caregiver education, and improving treatment access.

Jessica Dunne, PhD, discusses why adult T1D is frequently misdiagnosed as T2D and how autoantibody testing could close the diagnostic gap.

Josean Gonzalez, PharmD, BCPP, discusses the expanding role of pharmacists in Alzheimer disease care, Baptist Health South Florida’s multidisciplinary approach, and the promise of emerging therapies for patients with cognitive disorders.

Dave Dixon, PharmD, examines why SGLT2 inhibitor and GLP-1 uptake remain low and how pharmacists can bridge the gap between evidence and implementation.

Jillian Fetzner, MSN, APRN-CNP, described how integrating pharmacists into a collaborative practice agreement processed 3750 diabetes refill requests without provider involvement.

Dave Dixon, PharmD, breaks down the key cardiovascular and kidney risk management updates in the 2026 ADA Standards of Care and what they mean for pharmacy practice.

Alyson Myers, MD, explains why expanded telehealth access, technology equity, and pharmacist partnerships are essential — not optional.

Real-world adoption of talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer highlights ongoing gaps in homologous recombination (HR) biomarker testing across prostate cancer care.

Erica Marini, PharmD, and guest, Millad Sobhanian, PharmD, BCPS, discuss 3 major Alzheimer disease developments including a newly approved agitation therapy, the delayed FDA decision on lecanemab subcutaneous initiation dosing, and a controversial review on anti-amyloid therapies.

Real-world evidence is helping improve HER2-low metastatic breast cancer care, identify treatment gaps, and better understand patient distress and outcomes.

Electronic patient-reported outcome (ePRO) monitoring platforms may improve symptom management, reduce hospitalizations, and help patients remain on cancer therapy longer through earlier intervention and continuous remote support.

GLP-1 receptor agonists may be associated with improved survival outcomes and lower recurrence rates among women with breast cancer, obesity, and type 2 diabetes.

Jessica Paulus, ScD, discusses emerging real-world evidence suggesting GLP-1 receptor agonists may be associated with improved survival outcomes across several cancer types, while emphasizing the need for prospective clinical research.

SARC041 data shows the clinical benefits associated with abemaciclib in the treatment of patients with incredibly rare diseases.

APP-led benign hematology consult programs helped community oncology practices significantly reduce time to first appointment while strengthening interdisciplinary collaboration with pharmacists and physicians.

Emerging evidence links GLP-1 receptor agonists to improved breast cancer outcomes and the growing importance of metabolic health in survivorship care.